Caroline Hwang, MD
Gastroenterology · Los Angeles, CANPI 1003090085
Payments from drug & device makers
Across 948 payments — averaging $958.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$301K
- Janssen Research & Development, LLC$262K
- Bristol Myers Squibb$92K
- Johnson & Johnson$66K
- E.r. Squibb & Sons, L.L.C.$46K
- Takeda Pharmaceuticals U.S.A., Inc.$46K
- plus $95K from 21 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 384 | $301,398 |
| Janssen Research & Development, LLC | 81 | $261,715 |
| Bristol Myers Squibb | 68 | $92,225 |
| Johnson & Johnson | 154 | $65,654 |
| E.r. Squibb & Sons, L.L.C. | 24 | $46,482 |
| Takeda Pharmaceuticals U.S.A., Inc. | 75 | $45,617 |
| Janssen Scientific Affairs, LLC | 40 | $43,901 |
| Pfizer | 67 | $33,987 |
| Ferring Pharmaceuticals AS | 1 | $15,750 |
| Lilly USA, LLC | 18 | $440 |
| Cook Medical LLC | 2 | $256 |
| Celltrion USA Inc. | 8 | $181 |
| Medtronic(2 entities) | 2 | $157 |
| Sanofi | 5 | $155 |
| Aimmune Therapeutics, Inc. | 4 | $76 |
| Covidien LP | 1 | $75 |
| Welch Allyn | 1 | $64 |
| Regeneron Healthcare Solutions, Inc. | 2 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $43 |
| Braintree Laboratories, Inc. | 2 | $35 |
| Vivus LLC | 1 | $25 |
| QOL Medical, LLC | 1 | $23 |
| Merck | 1 | $21 |
| Fresenius Kabi USA, LLC | 1 | $21 |
| Ferring Pharmaceuticals Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $17 |
How this compares
$908,407 in reported general payments places this provider in the 95th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Los Angeles
- Gil MelmedLos Angeles$3M
- Bennett RothLos Angeles$2.8M
- Sammy SaabLos Angeles$2M
- Andres YarurLos Angeles$903K
- Brennan SpiegelLos Angeles$845K
- Nicholas KaryotakisLos Angeles$710K
- Venkataraman MuthusamyLos Angeles$693K
- Sadeea AbbasiLos Angeles$556K
- Peter WinkleCypress$116.7M
- Manuchehr DaraniSanta Ana$17.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.